Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

150 mg qd po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during 2 years of follow-up

375 mg/m\^2 ivgtt, D0 of each 28-day cycle

Not specified, recommended regimen according to histopathologic type